99733-14-9

Usage

Uses

Used in Pharmaceutical and Biotechnology Industries:
Tert-butyl (4-guanidinobutyl)carbamate, 97% is used as a protecting group in peptide synthesis for the preparation of various peptide-based drugs and therapeutics. Its role in protecting specific functional groups during the synthesis process ensures the successful formation of the desired peptide sequences, enhancing the efficiency and yield of the overall synthesis.
Used in Organic Synthesis:
Tert-butyl (4-guanidinobutyl)carbamate, 97% is also used as a reagent in organic synthesis. Its unique chemical properties and high purity make it a valuable component in the development of various organic compounds and materials. Its versatility in organic synthesis contributes to the advancement of chemical research and the creation of novel compounds with potential applications in various fields.

Upstream product

• 68076-36-8 1-amino-4-[(tert-butyloxycarbonyl)amino]butane 
• 41306-45-0 N,S-dimethylisothiourea hydroiodide 

Relevant academic research and scientific papers

Cytotoxic α-Halogenoacrylic Derivatives of Distamycin A and Congeners

The mechanism of action of many antitumor agents involves DNA damage, either by direct binding of the drug to DNA or to DNA-binding proteins. However, most of the DNA-interacting agents have only a limited degree of sequence specificity, which implies that they may hit all the cellular genes. DNA minor groove binders, among which the derivatives of distamycin A play an important role, could provide significant improvement in cancer management, increasing gene specificity, due to high selectivity of interaction with thymine-adenine (TA) rich sequences. We now report and discuss the synthesis, the in vitro and in vivo activities, and some mechanistic features of α-halogenoacrylamido derivatives of distamycin A. The final result of this work was the selection of brostallicin 17 (PNU-166196). Brostallicin, presently in phase II clinical trials, shows a broad spectrum of antitumor activity and an apoptotic effect higher than distamycin derivative tallimustine. An important in vitro toxicological feature of brostallicin is the very good ratio between myelotoxicity on human haematopoietic progenitor cells and cytotoxicity on tumor cells, in comparison with clinically tested DNA minor groove binders. A peculiarity of brostallicin is its in vitro reactivity in the DNA alkylation assays only in the presence of glutathione. Moreover brostallicin's antitumor activity, both in in vitro and in vivo tumor models, is higher in the presence of increased levels of glutathione/glutathione-S-tranferases. These findings contribute to the definition of brostallicin as a novel anticancer agent that differs from other minor groove binders and alkylating agents for both the profile of activity and the mechanism of action and to. classify the α-bromoacrylamido derivatives of distamycin as a new class of cytotoxics. Moreover, due to its interaction with glutathione, brostallicin may have a role for the tailored treatment of tumors characterized by constitutive or therapy-induced overexpression of glutathione/glutathione-S-tranferase levels.